microRNAs in the pathophysiology of CKD-MBD: Biomarkers and innovative drugs - Aix-Marseille Université Access content directly
Journal Articles Biochimica et Biophysica Acta - Molecular Basis of Disease Year : 2017

microRNAs in the pathophysiology of CKD-MBD: Biomarkers and innovative drugs

Abstract

microRNAs comprise a novel class of endogenous small non-coding RNAs that have been shown to be implicated in both vascular damage and bone pathophysiology. Chronic kidney disease-mineral bone disorder (CKD-MBD) is characterized by vessel and bone damage secondary to progressive loss of kidney function. In this review, we will describe how several microRNAs have been implicated, in recent years, in cellular and animal models of CKD-MBD, and have been very recently shown to be deregulated in patients with CKD. Particular emphasis has been placed on the endothelial-specific miR-126, a potential biomarker of endothelial dysfunction, and miR-155 and miR-223, which play a role in both vascular smooth muscle cells and osteoclasts, with an impact on the vascular calcification and osteoporosis process. Finally, as these microRNAs may constitute useful targets to prevent or treat complications of CKD-MBD, we will discuss their potential as innovative drugs, describe how they could be delivered in a timely and specific way to vessels and bone by using the most recent techniques such as nanotechnology, viral vectors or CRISPR gene targeting.

Dates and versions

hal-01464865 , version 1 (10-02-2017)

Identifiers

Cite

Valérie Metzinger, Stéphane Burtey, Pierre Maitrias, Ziad A Massy, Laurent Metzinger. microRNAs in the pathophysiology of CKD-MBD: Biomarkers and innovative drugs. Biochimica et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, pp.337-345. ⟨10.1016/j.bbadis.2016.10.027⟩. ⟨hal-01464865⟩
146 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More